Streetbeat News

Analyst Ratings

TSX:DHT

RBC Capital analyst Douglas Miehm has maintained an 'Outperform' rating on DRI Healthcare Trust and raised the price target from C$17 to C$18.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 12:28 pm

AZUL

BILL

BLK

CFG

CRL

FOXA

MELI

MPWR

PRI

SGHT

Several analyst forecasts were released on Monday, with price target changes for multiple companies. Keybanc raised the price target for BILL Holdings from $110 to $140, while Barclays boosted the price target for Azul S.A. from $8 to $14. Evercore ISI Group cut the price target for Citizens Financial Group from $32 to $29, and RBC Capital slashed Helmerich & Payne's price target from $53 to $45. Truist Securities boosted Primerica's price target from $220 to $240, and B of A Securities cut MercadoLibre's price target from $1,680 to $1,350. Citigroup lowered Charles River Laboratories' price target from $260 to $225, and Keefe, Bruyette & Woods raised the price target for BlackRock from $770 to $835. Raymond James boosted Monolithic Power Systems' price target from $500 to $570, and Wells Fargo slashed Fox Corporation's price target from $35 to $31. Citigroup cut Sight Sciences' price target from $15 to $9.

Portfolio Pulse from Lisa Levin

July 10, 2023 | 12:24 pm

FANG

LYV

META

RIG

On CNBC's 'Halftime Report Final Trades', several stocks were recommended. Josh Brown of Ritholtz Wealth Management recommended Live Nation Entertainment (LYV), citing an uptrend and a recent price target increase by Citigroup. Kevin Simpson named Home Depot (HD) as his final trade, despite the company's recent settlement of a lawsuit for underpaying workers. Bryn Talkington of Requisite Capital Management recommended Diamondback Energy (FANG) as energy stocks traded higher. Jim Lebenthal of Cerity Partners picked Transocean Ltd. (RIG) following an upgrade by Citigroup. Stephen Weiss of Short Hills Capital Partners named Meta Platforms (META) as his final trade, following the launch of Threads, a platform similar to Twitter.

Portfolio Pulse from Lisa Levin

July 10, 2023 | 12:24 pm

PBLA

Panbela Therapeutics, Inc. (NASDAQ:PBLA) announces that the independent Data Safety Monitoring Board (DSMB) of the Phase III ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has recommended that the study continue without modification. The ASPIRE Trial is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The company's pipeline consists of assets currently in clinical trials with an initial focus on familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention and ovarian cancer.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:17 pm

HELE

Helen Of Troy Ltd (NASDAQ:HELE) reported a Q1 FY24 sales decline of 6.6% YoY to $474.67 million, beating the analyst consensus of $465.36 million. The decrease was primarily due to lower sales in several categories. Adjusted EPS of $1.94 beat the analyst consensus of $1.60. The company continues its global restructuring plan, Project Pegasus, to improve efficiency and reduce costs. Helen Of Troy expects FY24 revenue of $1.965 billion - $2.015 billion against the consensus of $2 billion. HELE shares are trading higher by 9.29% at $123.00 in premarket.

Portfolio Pulse from Shivani Kumaresan

July 10, 2023 | 12:16 pm

BIVI

BioVie Inc. (NASDAQ:BIVI) will present data at the Alzheimer's Associate's International Conference showing how its drug candidate NE3107 regulates specific genes in a manner correlated with cognitive and biomarker improvements. The drug has shown potential in reducing DNA methylation, which is associated with various diseases. The data suggests that NE3107 may change the degree to which specific genes are epigenetically regulated, with potential functional correlations to cognition, inflammation, and Alzheimer's biomarkers.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:11 pm

CRWD

CrowdStrike Holdings (NASDAQ:CRWD) has received predominantly bullish ratings from analysts in the last quarter, with 13 bullish and 13 somewhat bullish ratings out of a total of 27. The average 12-month price target for the company is $178.78, which has increased by 7.57% over the past month.

Portfolio Pulse from Benzinga Insights

July 10, 2023 | 12:05 pm

CNK

Benchmark analyst Mike Hickey has reiterated a 'Buy' rating on Cinemark Hldgs (NYSE:CNK) and maintained a price target of $19.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 12:05 pm

CRL

In the last quarter, Charles River (NYSE:CRL) received two somewhat bullish and two indifferent ratings from analysts. The company's average 12-month price target is $246.25, a decrease of 5.29% from the previous average of $260.00. Analysts base their ratings on predictions of a company's future earnings and the predictability of its revenue streams.

Portfolio Pulse from Benzinga Insights

July 10, 2023 | 12:04 pm

IAS

In the last quarter, Integral Ad Science (NASDAQ:IAS) received a total of 13 analyst ratings, with 5 being bullish, 6 somewhat bullish, and 2 indifferent. The average 12-month price target for the company is $20.35, an increase of 18.52% over the past month. The high and low price targets are $25.00 and $16.00 respectively.

Portfolio Pulse from Benzinga Insights

July 10, 2023 | 12:04 pm